699 related articles for article (PubMed ID: 12477297)
1. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
2. Novel pharmacologic agents for type 2 diabetes.
Uwaifo GI; Ratner RE
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
[TBL] [Abstract][Full Text] [Related]
3. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
Dupre J
Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
5. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
6. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
Edelman SV; Weyer C
Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
[TBL] [Abstract][Full Text] [Related]
7. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
8. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 based therapies: differential effects on fasting and postprandial glucose.
Fineman MS; Cirincione BB; Maggs D; Diamant M
Diabetes Obes Metab; 2012 Aug; 14(8):675-88. PubMed ID: 22233527
[TBL] [Abstract][Full Text] [Related]
10. Optimizing diabetes treatment using an amylin analogue.
Edelman SV
Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
13. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
Weyer C; Maggs DG; Young AA; Kolterman OG
Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
15. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Purnell JQ; Weyer C
Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
[TBL] [Abstract][Full Text] [Related]
16. Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N
South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
[TBL] [Abstract][Full Text] [Related]
17. Clinical studies.
Young A
Adv Pharmacol; 2005; 52():289-320. PubMed ID: 16492555
[TBL] [Abstract][Full Text] [Related]
18. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
19. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
Blonde L; Baker DE; Davis SN; Ratner RE
J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
[TBL] [Abstract][Full Text] [Related]
20. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
